Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 516


Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the LYSA.

Sarkozy C, Molina T, Ghesquières H, Michallet AS, Dupuis J, Damotte D, Morsschauser F, Parrens M, Martin L, Dartigues P, Stamatoullas A, Hirsch P, Fabiani B, Bouabdallah K, Gomes da Silva M, Maerevoet M, Laurent C, Coiffier B, Salles G, Traverse-Glehen A.

Haematologica. 2016 Oct 6. pii: haematol.2016.152256.


Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK.

Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492.


Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.

Lassau N, Coiffier B, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Benatsou B, Bonastre J, Koscielny S.

Ann Oncol. 2016 Oct;27(10):1922-8. doi: 10.1093/annonc/mdw280.


ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group..

Ann Oncol. 2016 Aug;27(8):1378-81. doi: 10.1093/annonc/mdw239. No abstract available.


Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B.

Hematol Oncol. 2016 Jul 12. doi: 10.1002/hon.2320. No abstract available.


Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.

Traverse-Glehen A, Verney A, Gazzo S, Jallades L, Chabane K, Hayette S, Coiffier B, Callet-Bauchu E, Ffrench M, Felman P, Berger F, Baseggio L, Salles G.

Leuk Lymphoma. 2016 Jun 27:1-10.


Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.

Pettengell R, Sebban C, Zinzani PL, Derigs HG, Kravchenko S, Singer JW, Theocharous P, Wang L, Pavlyuk M, Makhloufi KM, Coiffier B.

Br J Haematol. 2016 Sep;174(5):692-9. doi: 10.1111/bjh.14101.


Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N.

J Clin Oncol. 2016 Jun 10;34(17):2028-36. doi: 10.1200/JCO.2015.64.5648.


Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G.

Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3.


A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H.

Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992.


Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.

Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B.

J Hematol Oncol. 2016 Mar 10;9:22. doi: 10.1186/s13045-016-0243-8.


Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W.

J Clin Oncol. 2016 Apr 20;34(12):1386-94. doi: 10.1200/JCO.2015.63.8387.


Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.

Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, Molina TJ, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Salles G, Tilly H, Leroy K, Jardin F.

Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305.


The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research..

Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739.


Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?

Bachy E, Coiffier B.

Lancet Haematol. 2015 Aug;2(8):e307-8. doi: 10.1016/S2352-3026(15)00116-7. No abstract available.


Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.

Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B.

Lancet Haematol. 2015 Apr;2(4):e160-5. doi: 10.1016/S2352-3026(15)00023-X.


Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C.

Ann Oncol. 2016 Mar;27(3):390-7. doi: 10.1093/annonc/mdv616. Review.


Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.

Sarkozy C, Traverse-Glehen A, Coiffier B.

Lancet Oncol. 2015 Nov;16(15):e555-67. doi: 10.1016/S1470-2045(15)00005-4. Review.


Primary refractory diffuse large B cell lymphoma in the rituximab era.

Sarkozy C, Coiffier B.

Curr Opin Oncol. 2015 Sep;27(5):377-83. doi: 10.1097/CCO.0000000000000209. Review.


Ofatumumab in the treatment of non-Hodgkin's lymphomas.

Karlin L, Coiffier B.

Expert Opin Biol Ther. 2015 Jul;15(7):1085-91. doi: 10.1517/14712598.2015.1055241. Review.

Items per page

Supplemental Content

Loading ...
Support Center